Why the study?
Does the development of antihirudin antibodies affect clinical outcomes and anticoagulatory effect in patients with HIT treated with lepirudin?
Population
196 evaluable patients with heparin-induced thrombocytopenia who received lepirudin as parenteral…
Comparison
Intravenous lepirudin for 2 to 10 days vs Patients who were antihirudin antibody negative
Design
Cohort
Authors
Loading...
Antihirudin antibodies were associated with lower mortality without excess adverse events in lepirudin-treated HIT; leaves open whether enhanced anticoagulation requires adjusted monitoring.
Does the development of antihirudin antibodies affect clinical outcomes and anticoagulatory effect in patients with HIT treated with lepirudin?
Antihirudin antibodies frequently develop during prolonged lepirudin treatment for HIT and can enhance its anticoagulatory effect, necessitating daily monitoring to avoid bleeding.
Eichler et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: